Natural Capsules (NATCAPSUQ)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At ₹157 per share, the market assigns Natural Capsules a value exactly equal to its book value of ₹157.03. That is an interesting starting point for a Graham-style investor, because the downside is partly protected by assets. But book value is only a starting point. The real question is whether the business can generate acceptable returns on those assets, and here the evidence is disturbing. Return on equity is a meagre 5.08%, and return on capital employed just 2.67% — far below what a sound pharmaceutical company should produce. Sales have contracted by 13.87%, and the latest quarter delivered a net loss of ₹7 crore on sales of ₹38 crore. The profit growth figure of -6572% is not meaningful except to confirm that profits have collapsed into losses. Piotroski F-score of 3/9 further confirms that the company's financial health is deteriorating. There is no moat that I can see: no pricing power, no dominant market share, no evidence of efficient operations. The only positive is that debt is moderate, with debt-equity at 0.46, and promoter holding of 51.26% suggests that insiders have their capital at risk. But as Buffett says, turnaround is seldom a happy ending. With no dividend and a stock trading near its 52-week low, the market has already taken the air out of the story. This is not a fast grower or stalwart; it is a turnaround or possibly an asset play if the assets are worth more than the stated book value. I would wait for evidence of stabilising sales, positive cash flow, and a credible plan to restore margins before committing capital.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer